Steven Stein, M.D. joined Incyte in 2015 and currently serves as the Company’s Executive Vice President and Chief Medical Officer. In his role as CMO, he oversees verticals including clinical development, clinical operations, pharmacovigilance, statistics and data management and regulatory affairs. Prior to joining Incyte, he worked at Novartis Pharmaceuticals Corporation, most recently as Senior Vice President, U.S. Clinical Development & Medical Affairs for Novartis Oncology. Prior to his tenure at Novartis, Dr. Stein worked at GSK (formerly GlaxoSmithKline) as Vice President, Global Oncology, Clinical Development and as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein was previously an Assistant Professor in the Department of Medicine at the University of Pennsylvania, where he had also completed a fellowship in Hematology and Oncology. Dr. Stein earned his medical degree from the University of Witwatersrand in Johannesburg, South Africa.

Paula Swain joined Incyte in 2002 and serves as the Company’s Executive Vice President of Global Human Resources & Facilities. Additionally, Ms. Swain chairs the Incyte Charitable Giving Foundation.  Before joining the company, Ms. Swain spent nearly 10 years with DuPont (acquired by Bristol Myers Squibb Company in 2001), where she served as Vice President and Senior Vice President of Global Human Resources. She has also held positions in human resource planning and employee relations with Chase Manhattan Bank, Marine Midland Bank and Delaware Trust Company. Ms. Swain received her Bachelor of Arts in Psychology from Rockhurst University and graduated from the Strategic Human Resources Planning program at Harvard Business School.

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer and was appointed Chairman of the Board of Directors in 2015.

During Mr. Hoppenot’s tenure, the company has tripled the number of clinical candidates in its portfolio, expanding beyond Oncology to include research and development in Inflammation & Autoimmunity. Under his leadership, revenue has increased by nearly 600%, which includes the addition of five new sources of potential revenue. With a goal to deliver medicines to patients worldwide, Incyte has expanded geographically and has operations in North America, Europe and Asia.

Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. He began his career at Novartis in 2003 as Chief Commercial Officer and later became President in 2010. Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.